Mario Roselli

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

In Vivo Tumor Targeting of a Recombinant Single-Chain Antigen-Binding Protein

David Colcher, Robert E. Bird, Mario Roselli et al. · JNCI Journal of the National Cancer Institute · 1990 · 303 citations

Pharmacy, Molecular Biology, Oncology +17

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

Mario Roselli, Vittore Cereda, Maria Giovanna di Bari et al. · OncoImmunology · 2013 · 186 citations · Full text

Medicine, Immunology, Oncology +17

Breast Cancer Prognosis Using a Machine Learning Approach

Patrizia Ferroni, Fabio Massimo Zanzotto, Silvia Riondino et al. · Cancers · 2019 · 185 citations · Full text

Computing, Health Informatics, Oncology +17

Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia

Claudia Basile, David Della‐Morte, Francesco Cacciatore et al. · Experimental Gerontology · 2014 · 174 citations

Medicine, Geriatric Medicine, Frailty +15